What is Vaxess Technologies?
Vaxess Technologies operates at the intersection of immunology, mechanical engineering, and chemistry to address critical gaps in global healthcare delivery. By developing a proprietary transdermal patch, the company aims to eliminate the reliance on traditional needle-based injections and cold-chain logistics. This approach not only enhances patient compliance but also expands the reach of essential therapies into underserved or remote environments. As a leader in the biomedical innovation space, Vaxess is positioned to disrupt the traditional pharmaceutical supply chain by enabling decentralized, patient-centric administration of vaccines and complex therapeutics.
How much funding has Vaxess Technologies raised?
Vaxess Technologies has raised a total of $158.9M across 10 funding rounds:
Private Equity
$862K
Series A
$82M
Debt
$150K
Series B
$27M
Other Financing Round
$10M
Other Financing Round
$9M
Other Financing Round
$12M
Other Financing Round
$9M
Debt
$7.9M
Private Equity (2016): $862K, investors not publicly disclosed
Series A (2019): $82M supported by The Engine and Bioinnovation Capital
Debt (2020): $150K featuring PPP
Series B (2022): $27M backed by Mission BioCapital, The Engine, and Global Health Investment Corporation
Other Financing Round (2023): $10M with participation from Mission BioCapital and RA Capital Management
Other Financing Round (2023): $9M led by Ulu Ventures, The Engine, and RA Capital Management
Other Financing Round (2024): $12M supported by RA Capital Management, Mission BioCapital, and Engine Ventures
Other Financing Round (2025): $9M featuring RA Capital Management and Engine Ventures
Debt (2025): $7.9M, investors not publicly disclosed
Key Investors in Vaxess Technologies
RA Capital Management
A multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies, utilizing its TechAtlas think tank to guide strategic decisions.
Mission BioCapital
A venture capital firm providing early-stage capital and mentorship to life science entrepreneurs, with a focus on accelerating the journey from scientific discovery to medical breakthroughs.
The Engine
A venture firm built by MIT that invests in Tough Tech, applying cutting-edge scientific research to solve complex challenges in human health and infrastructure.
What's next for Vaxess Technologies?
With the support of its latest capital injection, Vaxess Technologies is poised to accelerate the clinical validation and manufacturing scale-up of its core platform. The strategic focus will likely shift toward optimizing the applicator technology for mass-market deployment and expanding its pipeline of therapeutic candidates. By leveraging the operational expertise of its venture partners, the company is well-positioned to navigate the regulatory landscape and transition from research-stage development to commercial-scale impact, ultimately setting a new standard for global vaccine accessibility and patient-led care.
See full Vaxess Technologies company page
